4.95

0.20% -0.010

After Hours: 4.86 -0.09 -1.82%

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $4.95, with a volume of 30,275. It is down -0.20% in the last 24 hours and down -13.16% over the past month. Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Previous Close:

$4.96

Open:

$4.95

24h Volume:

30,275

Relative Volume:

0.45

Market Cap:

$42.63M

Revenue:

Net Income/Loss:

$-34.77M

P/E Ratio:

-1.4956

EPS:

-3.3097

Net Cash Flow:

$-29.79M

1W Performance:

+4.32%

1M Performance:

-13.16%

6M Performance:

-57.68%

1Y Performance:

-60.32%

1-Day Range:

$4.8631

$5.055

1-Week Range:

$4.6601

$5.10

52-Week Range:

$3.76

$19.35

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

206.588.0256

Address

1448 NW MARKET STREET, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2026-05-12

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	4.95	42.71M	0	-34.77M	-29.79M	-3.3097
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

01:00 AM

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

01:00 AM

May 22, 2026

ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

May 22, 2026

May 21, 2026

ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

May 21, 2026

May 20, 2026

Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union

May 20, 2026

Atossa Therapeutics (ATOS) director granted 10,000 RSUs vesting after 2026 - Stock Titan

May 14, 2026

ATOS (ATOS) director Stephen Galli receives 10,000 RSU equity grant - Stock Titan

May 14, 2026

Atossa Therapeutics (ATOS) director granted 10,000 RSUs in stock award - Stock Titan

May 14, 2026

Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant - Stock Titan

May 14, 2026

Atossa Therapeutics (ATOS) director granted 10,000-share RSU award - Stock Titan

May 14, 2026

Atossa Therapeutics (NASDAQ: ATOS) director receives 10,000 RSUs award - Stock Titan

May 14, 2026

Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential - Traders Union

May 14, 2026

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - BioSpace

May 14, 2026